It's shaping up to be a big year for Boehringer Ingelheim—at least if the FDA plays ball. | Boehringer Chief Medical Officer ...

Veeva Systems (NYSE: VEEV) today announced Boehringer Ingelheim is the latest top 20 biopharma to standardize customer data ...

Boehringer Ingelheim reported positive growth in the first half of 2025, with group net sales growing by 6.3%* to EUR 14.0 billion.

The data from 2019 to 2023 show rapid uptake of the drugs alongside wide patient- and practice-level variations.

Sen. Tim Kaine has been involved with bringing pharmaceutical reseach and development to central Virginia since his days on ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab) ...

LEO Pharma’s Anzupgo (delgocitinib) cream has been approved by the US Food and Drug Administration (FDA) to treat adults with ...

LEO Pharma A/S agreed to acquire the global rights for skin disease drug Spevigo from Boehringer Ingelheim GmbH, as the ...

Boehringer Ingelheim and SoundTalks end their partnership, but what does this mean for pig farmers? Find out about the future ...

the white paper underscores a widespread crisis of underappreciation, operational strain and burnout, directly impacting the ...